Ireland
--:--IST
Enrolling by invitation Phase 2

A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)

NCT06275620 · tracked via the Priya Life Science USA tracker
Phase
Phase 2
Started
2023-11-14
Last updated
2024-10-30

Condition(s) studied

X-Linked Retinitis Pigmentosa

Investigational drug(s) / intervention(s)

AGTC-501 (high dose and standard corticosteroid regimen) →AGTC-501 (low dose and standard corticosteroid regimen) →AGTC-501 (high dose and modified corticosteroid regimen) →

AGTC-501 (high dose and standard corticosteroid regimen): Adeno-associated virus vector expressing a human RPGR gene

AGTC-501 (low dose and standard corticosteroid regimen): Adeno-associated virus vector expressing a human RPGR gene

AGTC-501 (high dose and modified corticosteroid regimen): Adeno-associated virus vector expressing a human RPGR gene

Study summary

This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a full-length AAV vector-based gene therapy targeting RPGR protein.

Eligibility

Sex
MALE
Min age
12 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Be ≥12 years of age * Have one eye previously treated with an AAV vector-based gene therapy designed to provide full-length functioning RPGR protein. * Have a BCVA no better than 78 letters and no worse than 34 letters * Be able to perform all tests of visual and retinal function and structure in both eyes based on the participant's reliability and fixation, per the Investigator's discretion. * Have detectable baseline mean macular sensitivity measured by MAIA microperimetry, as determined by the Investigator and confirmed by the Central Reading Center (CRC). * Have detectable EZ line in the study eye as assessed by SD-OCT and confirmed by the CRC. Exclusion Criteria: * Have other known disease-causing mutations documented in the participant's medical history or identified through a retinal dystrophy gene panel that, in the opinion of the Investigator, would interfere with the potential therapeutic effect of the study agent or the quality of the assessments. * Have pre-existing eye conditions that would preclude the planned surgery, interfere with the interpretation of study endpoints, or increase the risk of surgical complications * Had intraocular surgery within 90 days of study treatment administration. * Have any active ocular/intraocular infection or inflammation * Have a history of steroid-induced raised IOP of \>25 mmHg following corticosteroid exposure, despite topical IOP-lowering pharmacologic therapy.

Primary outcome measure(s)

  • The primary safety outcome is the number of participants experiencing Grade 3 or higher local (ocular) or non-ocular treatment-emergent adverse events, including treatment-emergent serious adverse events (SAEs). — Day 0 - Month 12
  • The primary safety outcome is the proportion of participants experiencing Grade 3 or higher local (ocular) or non-ocular treatment-emergent adverse events, including treatment-emergent serious adverse events (SAEs). — Day 0 - Month 12

Trial sites (7)

FacilityCityRegionStatus
University of Florida Jacksonville Florida
Bascom Palmer Eye Institute Miami Florida
Boston Children's Hospital Boston Massachusetts
Cincinnati Eye Institute Cincinnati Ohio
Cleveland Clinic Cleveland Ohio
Casey Eye Institute Portland Oregon
Retina Foundation of the Southwest Dallas Texas
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06275620 on ClinicalTrials.gov ↗ ← All trials in the USA